Scientists are increasingly investigating retatrutide, a novel drug developed by Eli Lilly, as a possible advance in weight loss . Unlike many previous approaches, retatrutide is a dual -action receptor targeting simultaneously GLP-1 and GIP, hormones that influence satiety and glucose balance. … Read More